Oragenics Inc
OGEN3.850USD
+0.320+9.07%
Market hours （ET）Quotes delayed by 15 min
82.68MMarket Cap
LossP/E TTM
More Details of Oragenics Inc Company
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
Company Info
Company codeOGEN
Company nameOragenics Inc
IPO dateJul 09, 2003
Founded at1996
CEOMs. Janet Huffman
Number of employees3
Security typeOrdinary Share
Fiscal year-endJul 09
Address1990 Main Street
CitySARASOTA
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code34236
Phone18132867900
Websitehttps://www.oragenics.com/
Company codeOGEN
IPO dateJul 09, 2003
Founded at1996
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
1.16K
--
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Interim Executive Chairman of the Board
Interim Executive Chairman of the Board
849.00
--
Ms. Kimberly M. Murphy
Ms. Kimberly M. Murphy
Director
Director
833.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Dr. James Kelly, M.D.
Dr. James Kelly, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Mr. Tirth T. Patel
Mr. Tirth T. Patel
Vice President
Vice President
--
--
Dr. William (Frank) Peacock, M.D.
Dr. William (Frank) Peacock, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
1.16K
--
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Interim Executive Chairman of the Board
Interim Executive Chairman of the Board
849.00
--
Ms. Kimberly M. Murphy
Ms. Kimberly M. Murphy
Director
Director
833.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Fri, May 16
Update time: Fri, May 16
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Odyssey Health, Inc
2.38%
Cassidy (Bruce A Sr)
1.65%
Geode Capital Management, L.L.C.
0.40%
Two Sigma Investments, LP
0.20%
Telling (Frederick W)
0.16%
Other
95.21%
Shareholder Statistics
Shareholder
Proportion
Odyssey Health, Inc
2.38%
Cassidy (Bruce A Sr)
1.65%
Geode Capital Management, L.L.C.
0.40%
Two Sigma Investments, LP
0.20%
Telling (Frederick W)
0.16%
Other
95.21%
Type
Shareholder
Proportion
Corporation
2.45%
Individual Investor
2.37%
Investment Advisor
0.52%
Investment Advisor/Hedge Fund
0.44%
Hedge Fund
0.24%
Venture Capital
0.12%
Other
93.87%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
54
3.11M
14.48%
+2.03M
2024Q4
61
3.11M
25.46%
+2.05M
2024Q3
59
1.22M
18.08%
+226.05K
2024Q2
58
1.45M
24.58%
+674.78K
2024Q1
57
1.51M
26.60%
+861.00K
2023Q4
59
1.13M
28.10%
+795.74K
2023Q3
58
266.28K
10.68%
+19.84K
2023Q2
53
93.56K
4.68%
-159.82K
2023Q1
59
99.61K
5.08%
-139.03K
2022Q4
61
223.18K
11.40%
-92.10K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Odyssey Health, Inc
511.31K
2.38%
+511.31K
--
Dec 28, 2023
Cassidy (Bruce A Sr)
354.73K
1.65%
+102.00
+0.03%
Mar 10, 2025
Geode Capital Management, L.L.C.
38.48K
0.18%
+2.76K
+7.73%
Dec 31, 2024
Two Sigma Investments, LP
36.64K
0.17%
+36.64K
--
Dec 31, 2024
Telling (Frederick W)
34.75K
0.16%
--
--
Mar 10, 2025
GSB Wealth Management, LLC
20.20K
0.09%
--
--
Dec 31, 2024
Koski (Robert C)
27.94K
0.13%
--
--
Mar 10, 2025
Dunton (Alan W)
25.62K
0.12%
--
--
Mar 10, 2025
Pope (Charles L)
25.47K
0.12%
--
--
Mar 10, 2025
Murphy (Kimberly M)
25.00K
0.12%
--
--
Mar 10, 2025
View more
Related ETFs
Update time: 7 hours ago
Update time: 7 hours ago
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Date
Type
Ratio
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
